Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amanda Day

Physician Assistant, Medical Dothan, AL Physician Assistant

NPI 1730432311 CMS profile 11105818

106 Westside Dr, Dothan, AL 36303

Open in the dashboard

General payments

$3,515

225 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Day of Dothan, AL is reported in the CMS Open Payments database as having received $3,515 across 225 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $647 39
2024 General $705 55
2023 General $537 42
2022 General $829 40
2021 General $796 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Day
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Amanda Day were reported at $647. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Amanda Day Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $796 $156 $41–$563 $132
2022 $829 $185 $55–$649 $149
2023 $537 $199 $58–$717 $160
2024 $705 $206 $62–$740 $164
2025 $647 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. UCB, Inc. $683 80 payments
  2. AbbVie, Inc. $671 39 payments
  3. Janssen Biotech, Inc. $371 14 payments
  4. Genzyme Corporation $284 15 payments
  5. Regeneron Healthcare Solutions, Inc. $264 10 payments
  6. Novartis Pharmaceuticals Corporation $251 16 payments
  7. Amgen Inc. $206 9 payments
  8. Lilly USA, LLC $172 8 payments
  9. Sun Pharmaceutical Industries Inc. $160 6 payments
  10. Pfizer Inc. $108 7 payments
  11. Other $344 21 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,199 220 payments
  2. Education $316 5 payments
Products named General payments · program years 2021–2025
  1. Bimzelx $483 52 payments
  2. SKYRIZI $383 21 payments
  3. DUPIXENT $363 19 payments
  4. TREMFYA $323 11 payments
  5. Otezla $206 9 payments
  6. Cimzia $200 28 payments
  7. TALTZ $158 7 payments
  8. COSENTYX $157 11 payments
  9. HUMIRA $152 11 payments
  10. LIBTAYO $150 7 payments
  11. Other $1,523 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,007

Median for Physician Assistant: 241

Drug cost

$648,409

Median for Physician Assistant: $4,110

Branded share of claims

19%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 52 $203,130
Dupixent Syringe Dupilumab Brand 27 $112,195
Cosentyx Sensoready (2 Pens) Secukinumab Brand 12 $112,082
Cosentyx Unoready Pen Secukinumab Brand 12 $110,910
Otezla Apremilast Brand 16 $79,272
Clobetasol Propionate Generic 101 $10,359
Betamethasone Dipropionate Generic 78 $4,847
Tacrolimus Generic 13 $2,983
Doxycycline Hyclate Generic 101 $2,858
Triamcinolone Acetonide Generic 179 $2,004

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$170,167

Of which drugs: $7,465

Medicare patients

591

Average age 75

Services billed

3,570

309 women, 282 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 32%
Ischemic heart disease 28%
Chronic kidney disease 27%
Atrial fibrillation 20%
Heart failure 18%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 54 $30

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Bimzelx
  • UCB, Inc. $214
$214 — —
Otezla
  • Amgen Inc. $101
$101 16 —
SKYRIZI
  • AbbVie, Inc. $93
$93 — —
TREMFYA
  • Janssen Biotech, Inc. $50
$50 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

225 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record